MedBlogs

Targeted Cancer Therapies – Current Status and Future Prospects

Posted by kaushik2015 on Thu, 13 Aug 2015

(2) No of Views (4393)

Member SignIn
Please login to rate

Email
Password


Forgot Password? Sign up now

1 rating

Kaushik Bharati, PhDIn the field of anticancer therapy, a number of strategies for improving the therapeutic efficacy of anticancer agents have emerged over the past several decades. These strategies essentially involve strategies for targeted anticancer drug delivery. Several new classes of targeted anticancer therapies have recently been introduced for routine clinical use. While conventional chemotherapy targets all dividing cells, these molecules target specifically the cancer cells. These i... Read More

Share this MedBlog

Tags :

Post Your Comments

This is an open forum for the public. Please follow our Community Guidelines when posting any material. You are welcome to be critical or controversial, but avoid getting personal, abusive or offensive and try to keep your postings brief. All postings are being constantly reviewed for spam and irrelevant material (such as product advertisement or personal advertisements). Any posting that does not conform to our policy and 'Terms of Use' are deleted.
Remember threads are for only feedback and discussion. We will not use this material for publishing papers or advertisements.
You need to be registered with Medwonders to post any item. If you are a New User please register. You will be re-directed back to this page.

2 Comment(s)


kaushik2015 29 Aug 15 10:31 PM Thanks Partha for your kinds words of appreciation. Actually, particularly in the Indian context and other LMICs, the problem lies in the affordability of these drugs. For example, monoclonal antibodies (mAb) like trastazumab (Herceptin) for breast cancer, costs anywhere between ~ Rs. 19,000/- to ~ Rs. 60,000/- per vial, depending on the amount of the mAb-drug conjugate present. Therefore, the prohibitively high price of the drugs is the major hindrance to affordability. This needs to be solved in order to make the drugs more accessible to the general public.
ParthaDey 29 Aug 15 12:37 PM Thx for this excellent write up, you have narrated a very complex scientific situation in a simple manner so that everyone can understand the context and how the future is shaping up to fight against cancer. Improved targeted therapy will enhance the efficacy of the drug while side effects will be history for chemotherapy. I recall patients are scared of chemo because of associated hair loss factor. I have recently got an opportunity to explore the IBM Watson's cognitive capability to help physician to identify the most appropriate drug regime for a patient based on evidence, I believe combination of Watson's cognitive capability and targeted therapy will be lethal for cancer.

kaushik2015

29 Aug 15
10:31 PM

Thanks Partha for your kinds words of appreciation. Actually, particularly in the Indian context and other LMICs, the problem lies in the affordability of these drugs. For example, monoclonal antibodies (mAb) like trastazumab (Herceptin) for breast cancer, costs anywhere between ~ Rs. 19,000/- to ~ Rs. 60,000/- per vial, depending on the amount of the mAb-drug conjugate present. Therefore, the prohibitively high price of the drugs is the major hindrance to affordability. This needs to be solved in order to make the drugs more accessible to the general public.

ParthaDey

29 Aug 15
12:37 PM

Thx for this excellent write up, you have narrated a very complex scientific situation in a simple manner so that everyone can understand the context and how the future is shaping up to fight against cancer. Improved targeted therapy will enhance the efficacy of the drug while side effects will be history for chemotherapy. I recall patients are scared of chemo because of associated hair loss factor. I have recently got an opportunity to explore the IBM Watson's cognitive capability to help physician to identify the most appropriate drug regime for a patient based on evidence, I believe combination of Watson's cognitive capability and targeted therapy will be lethal for cancer.